Home » Clinical Trials » Leukemia » NCT04626726
NCT04626726

A Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of CAR-T Cell in the Treatment of Adult Relapsed Refractory (R/R) Acute Lymphoblastic Leukemia Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Study Summary

This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Relapsed Refractory (R/R) adult acute lymphoblastic leukemia bridging allogeneic hematopoietic stem cell transplantation.

Want to learn more about this trial?

Request More Info

Interventions

CD19 CAR-TDRUG
CD19 CAR-T infusion for patients with CD19 positive tumor cells
CD22 CAR-TDRUG
CD22 CAR-T infusion for patients with CD22 positive tumor cells
CD19+CD22 CAR-TDRUG
CD19+CD22 CAR-T infusion for patients with CD19 positive and CD22 positive tumor cells
FludarabineDRUG
25mg/㎡ for D-4、D-3 and D-2
CyclophosphamideDRUG
500mg/㎡ for D-3 and D-2

Study Locations

FacilityCityStateCountry
No.2 Hospital of Hebei Medical UniversityShijiazhuangHebeiChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026